Looking around us on a map, an optimist sees nothing but upside. Latin America is coming around to both medicinal and recreational marijuana. Europe is following suit. Meanwhile, across the border, 11 states plus D.C. are on the “legalized” ledger. Even the World Health Organization is recommending decriminalization. And ours is the only country prepared to supply cannabis on a global scale. But with great sales comes great responsibility. The push is on to standardize industry-wide to meet global regulations. The supply chain is being shored up. Most of our responses to the pull of demand involve spending more money to accommodate it. And the advent of legal edibles and oils is pushing us to diversify. It’s been a crazy year, and we’re here to predict what comes next.
If he did nothing else, Bruce Linton would be a cannabis industry hall of famer for founding the production giant Canopy Growth Corp. But the company’s erstwhile Chairman, CEO and Founder is seeking literally greener pastures these days, and is set to write the next chapter in the global governance of marijuana. Bruce will do a sit-down interview with Tony Chapman that will shine a light on what we’ll all be talking about in 2020.
Learn about NanoSphere’s patented “smart nanoparticles” of cannabinoids as alternatives to smoking, vaping and edibles. Hear about new products with precision dosaging for therapeutic and recreational cannabis.
It was prohibition that sent cannabis production indoors in the first place. Once there, technology took over, applying industrial techniques to warehouse growth. But the anticipated spike in demand post-legalization – and issues of increased energy expense and environmental group pressure – could lure the industry at least partly back into the daylight. This session will look at the benefits of outdoor cultivation, its simpler infrastructure, eco-friendliness, cost-effectiveness and its promise as a measure to boost supply and ward off shortage-driven black marketeering. And it will consider whether greenhouse cultivation is an energy-feasible compromise between indoor and outdoor.
Interviewer: Dr. Av Singh, Flemming & Singh Cannabis Inc.
An organism’s choice to reproduce with or without sex has long puzzled evolutionary biologists. Apomixis, a natural form of reproduction in plants whereby seeds are produced asexually to make genetic clones of the mother plant, has evolved repeatedly from sexual ancestors in many species. Apomixis is of interest on a number of levels, ranging from population genetics to evolution, but also from an applied perspective, as it represents a disruptive technology which could significantly change agricultural practices (e.g. fixing hybrid vigour in crops). The goal of my presentation will be to describe how we go from understanding the evolution of naturally-occurring asexual plants, to identifying the genes responsible for asexuality, to applying these genes to crop plants.
Cannabis is a unique plant based medicine in that it’s cultivation, processing, and development in understanding of effects has largely been restricted while other industries have developed innovative technology and techniques to increase efficiency, efficacy, and specificity of an end product. As legalization unfolds in many jurisdictions across the globe restrictions are being lifted on the development of cannabis-based products and with it the science and technological innovations required to serve both medicinal and adult-use markets. For companies to fully realize the potential that cannabis provides for product differentiation, research and innovation on how these novel compounds give rise to the effects desired by medical patients and adult-use consumers will need to expand greatly. In this talk a brief overview of our current theories and understanding on how complex synergies between cannabinoids, terpenes, and the receptor-compound interactions give rise to effects, and how understanding this dynamic will impact formulations of future products.
Cannabis microbiome sequencing has revealed interesting insights into microbial testing regulations. Cannabis endophytes and endofungal bacteria present serious challenges to culture based assessments of microbial risks and more accurate DNA based methods are required to limit clinical liability. To get a complete picture of the cannabis microbiome, we also constructed the most comprehensive Cannabis genome assembly. A blockchain based cannabis genetic registry for more immutable and transparent cannabis safety data tracking will be discussed.
Given Canada is a Federation we will have 13 different cannabis distribution regimes spread across the provinces and territories. There will be a mix of private and public offerings and if you want to understand how this will work and role out on October 17, come listen to a panel made of up of political insiders and industry representatives. This panel with provide you with the latest developments and offer insight towards how the future will look a year from legalization.
In the Future of Retail, Lori Bailey, Head of Retail at Canopy Growth, will speak to the incredible opportunity for creativity and innovation in cannabis retail. Focused on the upcoming adult use legal cannabis market, Lori will draw on more than twenty years of senior retail experience to highlight the commonalities and differences between traditional and cannabis retail while addressing the future of the sector in Canada. Her presentation will also cover retail essentials such as locations, personnel, experience design and community involvement.
Recent Comments